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Background:  National registry data shows the majority of implanted cardioverter defibrillators (ICD) are dual chamber devices (D-ICD). While 
D-ICDs are indicated in patients with concomitant pacing indications, whether to implant D-ICDs for the sole purpose of avoiding inappropriate 
shocks or a future upgrade procedure is equivocal. Given that D-ICDs may cause deleterious ventricular pacing, and given the problems with lead 
recalls, we hypothesized that in patients receiving an ICD, without a pacing indication, implanting single chamber defibrillator (S-ICD) will not result 
in frequent device upgrades and the clinical outcomes will be comparable to D-ICDs.
Methods:  We conducted a retrospective chart review of patients with ICDs implanted from January 1996 to January 2009 with ≥18 months of 
follow-up. Demographic, clinical, ECG and echocardiographic data were compared between patients with S-ICDs and D-ICDs. Patients were followed 
until their last office visit. Patients who had an upgrade were censored at that point.
Results:  Of the 924 patients with an ICD implant, 556 patients met inclusion criteria. 338/556 patients (61%) had S-ICDs. The mean duration 
of follow-up was 5 years in both groups. Patients with S-ICDs were younger (58 vs. 63 yrs; p<0.001), had faster heart rate at implant, (77 vs. 62 
bpm; p=0.01) and had a shorter QRS duration (110 vs.126 ms; p<0.001). Although the mean ejection fraction (EF) was identical at baseline (0.30 
in both groups), on last follow-up, S-ICD patients had a significant improvement in EF compared to D-ICD patients (0.37 vs. 0.31; P<0.001). Only 
37/338 (10%) patients needed an upgrade, 10 (3%) to a biventricular ICD. Importantly, hospitalization for heart failure were higher in patients with 
D-ICDs (36% vs. 24%, p<0.001), while inappropriate therapy was identical in both groups (17% in S-ICDs vs. 18% in D-ICDs p=NS).
Conclusions:  The majority of patients implanted with S-ICDs do not require an upgrade to a D-ICD and have similar rates of inappropriate therapy 
compared to patients with D-ICDs at a mean follow-up of 5 years. Since D-ICDs may lead to higher rate of hospitalizations for heart failure, S-ICD 
should be the device of choice in patients without pacing indications.
